$591 | SAVE $104 | Single User
$2423 | SAVE $427 | Site License
$4803 | SAVE $847 | Global License

The Impact of Mobile Health on Patient-Centric Disease Management

The Impact of Mobile Health on Patient-Centric Disease Management
[Lowest Price Guaranteed: $591]

Published by FirstWord Pharma: 01 Aug 2013 | 58 | In Stock
Related Topics: Banks , Boehringer Ingelheim , Business , Diabetes , FDA , GlaxoSmithKline , Healthcare , Pharmaceuticals



Banks use them. So does the travel industry. And tastemakers are harnessing their power every day. Now, it’s pharma’s turn to explore mobile and digital apps.

In an age where patients are well-informed and thus have a stronger-than-ever sense of ownership over their disease, there is mounting evidence that mobile health apps are affecting outcomes. Well-designed and intuitive, health apps can helping clinicians and healthcare providers better manage treatments, even after they leave the consulting rooms. As a result, patient adherence can improve.

So what’s in it for the pharmaceutical industry? Better health outcomes mean improved market access and greater brand loyalty. What’s more, as pharma taps into the mobile health industry—set to grow to US billion in three years, according to some estimates—real world data looped back from platforms will have far-reaching implications for drug development and clinical trials.

Through The Impact of Mobile Health on Patient-Centric Disease Management, FirstWord explores the emerging and exciting world of mobile and digital health apps. Based on interviews from nine industry experts, reviews of clinical and commercial opportunities and case studies, the report offers insight into app development, integration, and how the industry can capture the market now and in the future.


Report Highlights of The Impact of Mobile Health on Patient-Centric Disease Management include:

  • Expert opinion from those working at the forefront of the emerging mHealth industry, including experts from GlaxoSmithKline, Boehringer Ingelheim, UCB and Janssen Healthcare

  • Overview of clinical and commercial opportunities and realities. with implications for patients, clinicians and pharma

  • Case studies of new, established and successful platforms, covering diabetes, schizophrenia, adherence, cognitive behavioural therapy and epilepsy

  • Insight into the use of data for clinical patient management

  • Highlights

    Key Benefits

    While mobile and digital health apps are relatively new to pharma, there are clear signs they present excellent opportunities for the industry. In The Impact of Mobile Health on Patient-Centric Disease Management, FirstWord explores this exciting new area. Amongst the benefits, this report will help you to:

  • Understand the parameters of the booming mobile app business, as it applies to pharma

  • Learn the critical path for development of apps, platforms, gamification and optimising patient engagement

  • Understand how real world data gathered can make a difference in drug development and meeting demands for data from regulators and reimbursement agencies

  • Develop key knowledge about how mobile, digital and healthcare industries will grow together

  • Key Questions Answered

    The Impact of Mobile Health on Patient-Centric Disease Management answers key questions:

  • How can pharma harness the mobile and digital app industry?

  • What returns can pharma expect by developing mobile and digital apps?

  • What are the most successful apps to date and what garnered their success?

  • What are the key benefits of mobile technology for pharma, patients and physicians?

  • What is the future of digital and mobile health apps?

  • Puchase Reasons

    Selected quotes from the report

    “Use of these platforms means that patients are taking responsibility for themselves; that’s the magic bullet in a way, and that gets a win for everyone.” David Proudlock, GSK

    “Effectively, the healthcare professional or other stakeholder starts to have a better view of the patient’s clinical management outside of the consulting room, helping to prevent events, and enabling the provision of care for patients remotely. It’s a very different experience for patients, but it’s certainly something that patients tell us they want to see happen.” Michael Morgan-Curran from the GSMA

    “If we say to a payer, we have a drug but we also have a proven and remote monitoring device through a partner company so when a patient gets the drug they also get the mobile health device or app and we have proven studies, then we might be in a preferential position compared to a competitor molecule. We would have a better position from a market access perspective.” Wolfgang Renz, Boehringer Ingelheim

    Expert Views

  • Larry Brooks, Director, Business Model & Healthcare Innovation at Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

  • Tony Free, developer of iThinkSmarter smartphone app and cognitive behavioural therapist, Yorkshire, UK

  • Graham Howieson, CEO at GP Solutions (UK) Ltd, in Manchester, UK

  • Navin Joshi, Senior Director, Customer Solutions in Access to Medicines at GlaxoSmithKline

  • Marco Mohwinckel, partner at Janssen Healthcare Innovation, Europe, Middle East and Africa

  • Michael Morgan-Curran, Global Director of mHealth & Diabetes Programme Director at the GSMA (GSM Association)

  • Roger Palframan, Head of Innovation Super Networks at UCB

  • David Proudlock, Director, Innovation and Disruptive Technologies - UK Pharma at GlaxoSmithKline

  • Wolfgang Renz, Corporate Vice President, Business Model & Healthcare Innovation, Boehringer Ingelheim based in the U.S

  • Content Highlights

    Mobile and digital health apps are being developed with great success in pockets of the industry. In this report, you will discover:

  • The importance of digital platforms and mobile apps in providing integrated health solutions

  • The hidden value of mobile apps in collating, distributing and analysing real world data

  • The current state-of-play for regulations, leading up to the FDA’s pending guidance on mobile apps
  • Table of Contents
    for The Impact of Mobile Health on Patient-Centric Disease Management

    • 1.Executive summary

      1.1.Real world data

      1.2.Regulatory approval of mobile health devices

      1.3.Telecommunications operators

      1.4.Moving into the mobile and digital health space




      2.1.1.What is mobile health?

      2.2.Opportunity for pharmaceutical industry involvement

      2.3.Mobile health and digital health platforms: their importance to patients, physicians and the pharmaceutical industry

      2.4.What is meant by ‘mobile health’?

      2.4.1.Mobile health platforms in the doctor patient relationship

      2.5.The benefits of mobile health across the entire patient care pathway

      2.5.1.Research studies on stakeholder perceptions of mobile health

      2.6.Holistic health: the importance of engaging and empowering the whole patient through mobile health solutions

      2.6.1.Disease management: patients in the driving seat

      2.6.2.Patient-initiated responses have positive implications for clinical care and healthcare resources/systems

      2.6.3.Availability of mobile health platforms for patients

      2.6.4.Importance of integrating patient and physician needs within a digital or mobile health platform

      2.7.The challenges associated with designing and developing mobile health platforms for patient-related disease management

      2.8.Technologies need to ‘speak’ to each other

      2.8.1.Case study snapshots

      2.9.Early adopters of digital technology

      2.10.Understanding, acceptance and applicability of mobile health

      2.11.Incentivising patients to adhere to mobile health and digital platforms

      2.12.Gamification and novel approaches to mobile health platform development

      2.13.Mobile health platforms that integrate with clinical care

      3.Changing patient behaviours via mobile health and digital platforms: medication adherence, lifestyle factors, monitoring outcomes

      3.1.Non-adherence: increasing burden on healthcare system

      3.1.1.Understanding non-adherence

      3.1.2.Addressing non-adherence

      3.1.3.Technologies to tackle non-adherence

      4.The mobile health business case: what return can pharmaceutical companies expect for investing resources in mobile health and related digital platforms?

      4.1.Commercial pay-off for digital platforms

      4.2.Opening up new revenue streams

      4.3.Digital platforms that are associated with a medication

      4.4.Brand awareness and brand loyalty

      5.Mobile health for data monitoring and data exchange: clinical trials, real-world data, or health outcomes management

      5.1.A wealth of valuable data

      5.2.Big data

      5.3.Regulators and payers demand real world data

      5.4.Mobile health solutions for clinical trials

      6.Cautious steps into the world of digital and mobile health: minimising obstacles and maximising opportunities

      6.1.Regulations on the development of digital and mobile healthcare innovations

      6.1.1.FDA guidance

      6.2.Developing an evidence base for digital healthcare solutions

      6.3.Should pharmaceutical companies enter the digital platforms arena alone or in partnership?

      6.3.1.Boehringer Ingelheim and PatientsLikeMe

      6.3.2.Working with the telecommunications industry

      6.3.3.Digital, mobile and healthcare- how might they evolve together?

      6.3.4.Beyond the pill



    Additional Details


    FirstWord Pharma

    Publisher Information


    58 |

    Number of Pages


    Report Format


    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Physician Views: Ofev approved, Esbriet label updated – what impact on IPF-treating pulmonologists in the EU5?
    Scope The European idiopathic pulmonary fibrosis (IPF) community appears to have benefited from a nu...
    05 Feb 2015 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: The hepatitis C pricing war - what impact on prescribers?
    Scope In a surprise move, AbbVie agreed last month to provide its newly approved hepatitis C drug Vi...
    29 Jan 2015 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: What impact will the IMPROVE-IT study have on the treatment landscape?
    Scope As many have speculated, final data from Merck & Co.'s long-awaited IMPROVE-IT study has impli...
    20 Nov 2014 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: What impact has the controversy surrounding use of testosterone products had on urologists?
    Scope The number of prescription written for testosterone replacement therapy has skyrocketed over t...
    21 Aug 2014 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! ASCO 2014 -- Delegate Physicians Rate Influence and Impact
    IntroductionWhat hit the market at ASCO 2014?Oncology has been, and remains, an area of significant ...
    29 Jul 2014 by FirstWord Pharma USD $3,315 (normally
    USD $3,900)
    More Info
    SAVE 15% today! The Future of Biosimilars: mapping critical uncertainties and the impact of future events
    IntroductionThe Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Event...
    05 May 2014 by FirstWord Pharma USD $1,658 (normally
    USD $1,951)
    More Info
    SAVE 15% today! Physician Views: A Victoza competitor in waiting? – Can Eli Lilly's dulaglutide make an impact in the GLP-1 agonist market?
    Scope Last week, Eli Lilly confirmed that in the head-to-head AWARD-6 study its experimental GLP-1 a...
    05 Mar 2014 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Leveraging the iPad to Optimise MSL Impact
    IntroductionAlthough 80 percent of pharma companies have already deployed iPads to their sales reps,...
    01 Oct 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Pricing and Reimbursement Trends in the US: Impact of Comparative Effectiveness Research and Cost-Effectiveness Analysis
    IntroductionPublic healthcare costs are rising. Governments need to get them under control. In Europ...
    01 Jan 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    The Impact of Mobile Health on Patient-Centric Disease Management | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types


    Buy now using our secure payment system.

    We Stock...